IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.893,35 +310,44 (+0,53%)
Avidity Biosciences, Inc. (RNA)
Después del cierre:
Avidity Biosciences, Inc.
10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 253
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Sarah Boyce | President, CEO & Director | 998,88k | 1,16M | 1972 |
| Mr. Michael F. MacLean | Chief Financial & Chief Business Officer | 674,74k | N/A | 1966 |
| Ms. Teresa McCarthy | Chief Human Resources Officer | 628,79k | N/A | 1964 |
Descripción
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de Avidity Biosciences, Inc., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 9; Tablero: 9; Derechos de los accionistas: 8; Compensación: 8.
